Aclarion, a healthcare technology company focused on chronic low back pain, has announced the appointment of Jason Brosniak as Commercial Director for the Eastern U.S. This move is aimed at expanding market adoption and payer engagement for the company’s innovative technology, Nociscan.
Brosniak brings over 20 years of experience in driving revenue growth for MedTech companies, having previously worked at firms like Relievant Medsystems, Kyphon, and Intrinsic Therapeutics. His expertise in launching new technologies in areas such as spine and pain management is expected to facilitate the adoption of Nociscan in this densely populated region.
Brent Ness, CEO of Aclarion, said, “Jason’s hire represents another significant commercial milestone for the Company. The growing demand for Nociscan… necessitates additional commercial resources in the densely populated Eastern U.S.”
Brosniak noted, “Aclarion has built a platform with the power to meaningfully improve decision-making for both physicians and patients. With growing real-world evidence and increasing demand from clinicians, now is the right time to scale our commercial presence.”
This appointment follows the recent hiring of Dan Isherwood as the UK Commercial Director, reflecting Aclarion’s commitment to addressing the needs of the estimated 266 million people worldwide suffering from chronic low back pain.
The primary source was GlobeNewswire.
